NCT03460977 2026-03-13
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
Pfizer
BioNTech SE
AstraZeneca
DualityBio Inc.
Hansoh BioMedical R&D Company
Eli Lilly and Company